Literature DB >> 8289856

The treatment of multiple myeloma.

R Alexanian1, M Dimopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8289856     DOI： 10.1056/NEJM199402173300709

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  46 in total

Review 1.  [Role of high-dose chemotherapy in hematology and internal medicine/ oncology].

Authors:  A Engert; A Josting; M Reiser; D Söhngen; V Diehl
Journal:  Med Klin (Munich)       Date:  1999-08-15

2.  Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients.

Authors:  Hakan Kaya; Benjamin Peressini; Irfan Jawed; Danko Martincic; Ameer L Elaimy; Wayne T Lamoreaux; Robert K Fairbanks; Kevin A Weeks; Christopher M Lee
Journal:  Int J Hematol       Date:  2011-12-09       Impact factor: 2.490

Review 3.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

4.  Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.

Authors:  Norio Asou; Yoshiharu Izuno; Toshiya Okubo; Kazuhiko Ide; Hiroshi Ueno; Makoto Kawakita; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

5.  Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Authors:  Taiga Nishihori; Todd J Alekshun; Kenneth Shain; Daniel M Sullivan; Rachid Baz; Lia Perez; Joseph Pidala; Mohamed A Kharfan-Dabaja; Jose L Ochoa-Bayona; Hugo F Fernandez; Danielle N Yarde; Vasco Oliveira; William Fulp; Gang Han; Jongphil Kim; Dung-Tsa Chen; Jyoti Raychaudhuri; William Dalton; Claudio Anasetti; Melissa Alsina
Journal:  Br J Haematol       Date:  2012-03-26       Impact factor: 6.998

6.  Orthopedic Surgical Treatment and Perioperative Complications in Multiple Myeloma Bone Disease: Analysis of a Series (2009-2018).

Authors:  María Galán-Olleros; Javier Marco; David Oteo; Rafael Cristóbal-Bilbao; Elena Manrique; Roberto García-Maroto; Fernando Marco; Juan Luis Cebrián-Parra
Journal:  Ann Surg Oncol       Date:  2020-07-13       Impact factor: 5.344

7.  Complete C4 vertebral body destruction: a dramatic finding in a patient with a new diagnosis of myeloma.

Authors:  Andrew James Berg; Miguel Hernandez; Chandra Bhatia
Journal:  BMJ Case Rep       Date:  2014-02-20

Review 8.  Early versus deferred treatment for early stage multiple myeloma.

Authors:  Y He; K Wheatley; O Clark; A Glasmacher; H Ross; B Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2003

9.  Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Authors:  Lei Shi; Siqing Wang; Maurizio Zangari; Hongwei Xu; Thai M Cao; Chunjiao Xu; Yong Wu; Fang Xiao; Yinghong Liu; Ye Yang; Mohamed Salama; Guiyuan Li; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2010-05

10.  A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.

Authors:  Keun-Wook Lee; Tak Yun; Eun Kee Song; Im Il Na; Hyunchoon Shin; Soo-Mee Bang; Jae Hoon Lee; Seung Tae Lee; Jee Hyun Kim; Sung-Soo Yoon; Jong Seok Lee; Seonyang Park; Byoung Kook Kim; Noe Kyeong Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.